 |
|
Risk-Treatment Mismatch for Heart Failure—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: Dr Suissa raises 2 issues about our study of the risk-treatment mismatch in patients with heart failure. Regarding the potential impact of preadmission drug therapy, we performed the suggested stratified analysis and found that the risk-treatment mismatch was present for all strata. Among patients with left ventricular ejection fraction of less than 40% without limiting comorbidities who were taking ACE inhibitors or ARB antagonists before admission, treatment rates at discharge for low-, average-, and high-risk groups were 91%, 87%, and 74%, respectively (P for trend <.001). Among patients not taking ACE inhibitors or ARB antagonists before admission, the rates were 82%, 68%, and 43%, respectively (P for trend <.001). For patients taking  -adrenoreceptor antagonists before admission, treatment rates at discharge for low-, average-, and high-risk groups were 83%, 71%, and 50%, respectively (P for trend <.001) and in those not taking -adrenoreceptor antagonists before admission, . . . [Full Text of this Article]
Douglas S. Lee, MD, PhD;
Jack V. Tu, MD, PhD;
Andreas Laupacis, MD, MSc
alaupacis@ices.on.ca
Institute for Clinical Evaluative Sciences
University of Toronto
Toronto, Ontario
RELATED ARTICLES
Risk-Treatment Mismatch for Heart Failure
Samy Suissa
JAMA. 2005;294(24):3087.
EXTRACT
| FULL TEXT
Risk-Treatment Mismatch in the Pharmacotherapy of Heart Failure
Douglas S. Lee, Jack V. Tu, David N. Juurlink, David A. Alter, Dennis T. Ko, Peter C. Austin, Alice Chong, Therese A. Stukel, Daniel Levy, and Andreas Laupacis
JAMA. 2005;294(10):1240-1247.
ABSTRACT
| FULL TEXT
|
